H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

Henry Schein fourth quarter net sales increase 15.1% to $7.5 billion

Henry Schein, Inc., the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended December 25, 2010.

22 Feb 2011

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Vical Incorporated announced today that the company has extended its relationship with the U.S. Naval Medical Research Center to develop its platform technology for the rapid development and production of vaccines against emerging infectious diseases.

22 Feb 2011

Novavax announces final safety, immunogenicity results from H1N1 VLP vaccine at WHO meeting

Novavax, a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle pandemic influenza vaccine clinical trial in Mexico at the invitation-only 7th World Health Organization Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials.

19 Feb 2011

Daily Report Global Health Conversations: Global health funding and the FY11, FY12 budgets

As Congress considers both the FY11 and FY12 budgets, the Kaiser Daily Global Health Policy Report's Jaclyn Schiff spoke to Adam Wexler, a senior policy analyst for global health policy at the Kaiser Family Foundation, about the potential implications for global health funding.

18 Feb 2011

Flu vaccine update

This new vaccine which could become available in the United States in the next few years, is made by growing the influenza virus in cultures of animal cells rather than in the chicken eggs that have been used for more than five decades. This shortens the process by six months. Using animal cells, which are grown in enclosed steel tanks, also reduces the risk of bacterial contamination, which has led to shortages of seasonal vaccines in some years. The study was reported in The Lancet this Tuesday.

16 Feb 2011

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Baxter International Inc. announced today results of a study published in this week's issue of The Lancet that demonstrate effectiveness and tolerability of Baxter's PREFLUCEL in protecting against seasonal influenza.

From Baxter International Inc. 15 Feb 2011

February is again peak time for influenza across the nation

If you thought the regular seasonal flu has been late making its annual appearance, you might be surprised to learn that based on recent history, it's right on time.

15 Feb 2011

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the second quarter of Fiscal Year 2011.

14 Feb 2011

Rising number of livestock diseases threatens public health, food security in developing countries, report says

"A growing number of livestock, such as cows and pigs, are fuelling new animal epidemics worldwide and posing more severe problems in developing countries as it threatens their food security, according to a report [.pdf] released on Friday" during an international conference in New Delhi, India, on Leveraging Agriculture for Improving Nutrition & Health, Reuters reports (Lyn, 2/11).

14 Feb 2011

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2010.

10 Feb 2011

Vical 2010 net loss increases to $30.4 million

Vical Incorporated today reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010.

10 Feb 2011

Global Hygiene Council: Three simple steps to keep your family protected against infections

The Global Hygiene Council, a group of leading health and hygiene experts from around the world, convened in collaboration with the Centers for Disease Control and Prevention to discuss how proper hygiene plays a critical role in preventing the spread of illness and improving health around the world.

10 Feb 2011

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

Sartorius, a leading international laboratory and process equipment provider, successfully closed the year 2010. Sales revenue and earnings substantially surpassed the year-earlier figures. Financial guidance for the Group, which was raised during the course of 2010, was met and even exceeded for some targets.

From Sartorius 9 Feb 2011

Medicago granted FDA clearance for clinical development of seasonal flu vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States.

9 Feb 2011

Total flu cover with one shot

In a medical breakthrough, English scientists have developed a so-called “universal” vaccine to influenza - one that protects against all strains of the potentially deadly illness. This would do away with the need for a new vaccine each flu season they say. Seasonal flu affects up to 20 percent of the population and kills an average of 24,600 people each year. This vaccine would act against swine flu as well assure researchers.

8 Feb 2011

Anthem Blue Cross reminds seniors in Maine to get vaccinated against annual flu, pneumonia

While the seasonal flu can be very serious for patients of any age, senior citizens are particularly vulnerable. That's why Anthem Blue Cross and Blue Shield in Maine is reminding seniors across the state to get their annual flu and pneumonia vaccinations.

8 Feb 2011

Luminex 2010 revenue increases 17% to $141.6 million

Luminex Corporation today announced financial results for the fourth quarter and year ended December 31, 2010. Recent

From Luminex 8 Feb 2011

Stockpiling flu drugs, vaccines reduces impact of pandemic, but option out of reach for most countries, study finds

"Stockpiling antiviral flu drugs and vaccines saves lives and reduces disease in a flu pandemic," but the cost to maintain such a stockpile and deploy interventions in the event of an outbreak "is too expensive for around two thirds of the world's population, scientists said on Wednesday," Reuters reports.

3 Feb 2011

Public health experts: Improved community engagement needed to prevent pandemic spread

In the current issue of Journal of Public Health Management and Practice, public health experts assert that improved community engagement is needed to prevent the spread of pandemics.

3 Feb 2011

Swine flu shots linked to narcolepsy: Investigation continues

The vaccine used against swine flu has been linked to a disorder called narcolepsy among those aged four to 19. Narcolepsy involves people falling asleep without warning or sleeping excessively in the daytime. A preliminary study also “observed [an] increase in incidence of narcolepsy” among those given the vaccine.

2 Feb 2011

H1N1 News and Research

Henry Schein fourth quarter net sales increase 15.1% to $7.5 billion

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Novavax announces final safety, immunogenicity results from H1N1 VLP vaccine at WHO meeting

Daily Report Global Health Conversations: Global health funding and the FY11, FY12 budgets

Flu vaccine update

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

February is again peak time for influenza across the nation

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

Rising number of livestock diseases threatens public health, food security in developing countries, report says

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

Vical 2010 net loss increases to $30.4 million

Global Hygiene Council: Three simple steps to keep your family protected against infections

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

Medicago granted FDA clearance for clinical development of seasonal flu vaccine

Total flu cover with one shot

Anthem Blue Cross reminds seniors in Maine to get vaccinated against annual flu, pneumonia

Luminex 2010 revenue increases 17% to $141.6 million

Stockpiling flu drugs, vaccines reduces impact of pandemic, but option out of reach for most countries, study finds

Public health experts: Improved community engagement needed to prevent pandemic spread

Swine flu shots linked to narcolepsy: Investigation continues

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News